ROTHBLATT MARTINE A sold $4.8M of UTHR (indirect holdings)
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $501.84 ($493.81–$509.00, $4.77M total) across 14 trades on 2026-09-09 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale provides fresh data on insider activity but offers limited actionable insight due to its pre‑arranged nature.
Market read
Primary disclosure of an insider sale; modest relevance for short‑term traders monitoring UTHR.
What to watch
The 10b5‑1 plan means the sale may not reflect current sentiment; market may already price it in.
Background
SEC Form 4 filing reports insider transactions for public companies.
Ticker impact
Chairperson & CEO sold 9,500 shares for $4.8M via a pre‑arranged 10b5‑1 plan on 2026‑09‑09.
Potential modest dip in UTHR price over the next few days.
The sale size is moderate relative to total holdings and executed under a 10b5‑1 plan, limiting informational value.
Market effects
Minimal impact on the biotech/pharma sector; insider sales are routine.
No significant regional effect; UTHR trades primarily on US exchanges.
Limited global relevance; the filing is a standard SEC disclosure.
Counterpoint
The sale could be a red flag if the CEO is reducing exposure ahead of undisclosed issues.
Key entities
- CompanyUnited Therapeutics Corp
Biopharmaceutical company listed on NASDAQ under ticker UTHR.
- ExecutiveMartine A. Rothblatt
Chairperson & CEO of United Therapeutics.
